88 related articles for article (PubMed ID: 23012811)
1. [Renin-angiotensin system (RAS) as new molecular therapeutic targets in prostate cancer].
Kubota Y; Uemura H
Nihon Rinsho; 2012 Sep; 70(9):1604-12. PubMed ID: 23012811
[TBL] [Abstract][Full Text] [Related]
2. [Role of renin-angiotensin system in prostate cancer].
Uemura H; Kubota Y
Gan To Kagaku Ryoho; 2009 Aug; 36(8):1228-33. PubMed ID: 19692759
[TBL] [Abstract][Full Text] [Related]
3. Pharmacology and new perspectives of angiotensin II receptor blocker in prostate cancer treatment.
Uemura H; Ishiguro H; Kubota Y
Int J Urol; 2008 Jan; 15(1):19-26. PubMed ID: 18184167
[TBL] [Abstract][Full Text] [Related]
4. Role of the renin-angiotensin system in prostate cancer.
Chow L; Rezmann L; Catt KJ; Louis WJ; Frauman AG; Nahmias C; Louis SN
Mol Cell Endocrinol; 2009 Apr; 302(2):219-29. PubMed ID: 18824067
[TBL] [Abstract][Full Text] [Related]
5. Renin-angiotensin system is an important factor in hormone refractory prostate cancer.
Uemura H; Hasumi H; Ishiguro H; Teranishi J; Miyoshi Y; Kubota Y
Prostate; 2006 Jun; 66(8):822-30. PubMed ID: 16482568
[TBL] [Abstract][Full Text] [Related]
6. Regulation of androgen receptor expression through angiotensin II type 1 receptor in prostate cancer cells.
Hoshino K; Ishiguro H; Teranishi J; Yoshida S; Umemura S; Kubota Y; Uemura H
Prostate; 2011 Jun; 71(9):964-75. PubMed ID: 21541973
[TBL] [Abstract][Full Text] [Related]
7. Antiproliferative efficacy of angiotensin II receptor blockers in prostate cancer.
Uemura H; Nakaigawa N; Ishiguro H; Kubota Y
Curr Cancer Drug Targets; 2005 Aug; 5(5):307-23. PubMed ID: 16101380
[TBL] [Abstract][Full Text] [Related]
8. Engagement of renin-angiotensin system in prostate cancer.
Uemura H; Hoshino K; Kubota Y
Curr Cancer Drug Targets; 2011 May; 11(4):442-50. PubMed ID: 21395553
[TBL] [Abstract][Full Text] [Related]
9. [Application of angiotensin II receptor blocker in prostate cancer].
Uemura H; Kubota Y
Nihon Rinsho; 2009 Apr; 67(4):807-11. PubMed ID: 19348246
[TBL] [Abstract][Full Text] [Related]
10. The renin-angiotensin system in the breast and breast cancer.
Vinson GP; Barker S; Puddefoot JR
Endocr Relat Cancer; 2012 Feb; 19(1):R1-19. PubMed ID: 22180497
[TBL] [Abstract][Full Text] [Related]
11. Identification of EP4 as a potential target for the treatment of castration-resistant prostate cancer using a novel xenograft model.
Terada N; Shimizu Y; Kamba T; Inoue T; Maeno A; Kobayashi T; Nakamura E; Kamoto T; Kanaji T; Maruyama T; Mikami Y; Toda Y; Matsuoka T; Okuno Y; Tsujimoto G; Narumiya S; Ogawa O
Cancer Res; 2010 Feb; 70(4):1606-15. PubMed ID: 20145136
[TBL] [Abstract][Full Text] [Related]
12. Ets-1 and hypoxia inducible factor-1alpha inhibition by angiotensin II type-1 receptor blockade in hormone-refractory prostate cancer.
Kosaka T; Miyajima A; Shirotake S; Kikuchi E; Hasegawa M; Mikami S; Oya M
Prostate; 2010 Feb; 70(2):162-9. PubMed ID: 19760626
[TBL] [Abstract][Full Text] [Related]
13. Angiotensin II up-regulates PAX2 oncogene expression and activity in prostate cancer via the angiotensin II type I receptor.
Bose SK; Gibson W; Giri S; Nath N; Donald CD
Prostate; 2009 Sep; 69(12):1334-42. PubMed ID: 19517575
[TBL] [Abstract][Full Text] [Related]
14. [Role of renin-angiotensin system and antitumor effect of ARB in prostate cancer].
Uemura H; Hoshino K; Kubota Y
Nihon Rinsho; 2011 Jun; 69 Suppl 5():155-9. PubMed ID: 22207962
[No Abstract] [Full Text] [Related]
15. Novel strategies in the treatment of castration-resistant prostate cancer (Review).
Marech I; Vacca A; Ranieri G; Gnoni A; Dammacco F
Int J Oncol; 2012 May; 40(5):1313-20. PubMed ID: 22322981
[TBL] [Abstract][Full Text] [Related]
16. [Novel molecular targeting therapeutics for prostate cancer].
Uemura H; Nakaigawa N; Ishiguro H; Kubota Y
Nihon Rinsho; 2005 Feb; 63(2):339-44. PubMed ID: 15714989
[TBL] [Abstract][Full Text] [Related]
17. Angiotensin II receptor blocker: possibility of antitumor agent for prostate cancer.
Uemura H; Ishiguro H; Kubota Y
Mini Rev Med Chem; 2006 Jul; 6(7):835-44. PubMed ID: 16842133
[TBL] [Abstract][Full Text] [Related]
18. Carbidopa enhances antitumoral activity of bicalutamide on the androgen receptor-axis in castration-resistant prostate tumors.
Thomas C; Wafa LA; Lamoureux F; Cheng H; Fazli L; Gleave ME; Rennie PS
Prostate; 2012 Jun; 72(8):875-85. PubMed ID: 22072572
[TBL] [Abstract][Full Text] [Related]
19. Role of coordinated molecular alterations in the development of androgen-independent prostate cancer: an in vitro model that corroborates clinical observations.
Shi Y; Chatterjee SJ; Brands FH; Shi SR; Pootrakul L; Taylor CR; Datar R; Cote RJ
BJU Int; 2006 Jan; 97(1):170-8. PubMed ID: 16336351
[TBL] [Abstract][Full Text] [Related]
20. Angiotensin receptors in hormone-independent prostate cancer cell line DU145: presence of two variants of angiotensin type 1 receptor.
Sidorkiewicz M; Rebas E; Szymajda M; Ławnicka H; Pawlikowski M; Lachowicz A
Med Sci Monit; 2009 Apr; 15(4):BR106-10. PubMed ID: 19333191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
